On the Alert for Cytokine Storm: Immunopathology in COVID-19.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 32293098.
- Also identified by DOI 10.1002/art.41285 and PMC identifier 7262347.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19.
Medical subject headings
- Anti-Inflammatory Agents
- Coronavirus Infections
- Cytokine Release Syndrome
- Pneumonia, Viral